

San Francisco

Spring Group Meeting

SPECIALS

Radiation Oncology Committee

Radiation Oncology Committee

Leadership

Chair: Chul Ha, MD
 Vice-Chair: Lisa Kachnic, MD
 Executive Officer: Lisa Kachnic, MD
 Statisticians: Sam Callis, MS

Designates

Breast Committee Liaison: Reshma Jagsi, MD, DPhil
 BMT Committee Liaison: Austin Sim, MD
 Cancer Care Delivery Committee Liaison: Eileen Connolly, MD
 Prevention, Screening, & Surveillance
 Committee Liaison: Eileen Connolly, MD
 CNS Working Group Liaison: Tony Wang, MD
 Genitourinary Committee Liaison: James Yu, MD
 Gastrointestinal Committee Liaison: David Horowitz, MD
 Immunotherapeutics Committee Liaison: Robert Samstein, MD, PhD
 Lung Committee Liaison: Henry Park, MD
 Lymphoma Committee Liaison: Nick Figura, MD
 Melanoma Committee Liaison: Evan Wuthrick, MD
 Myeloma Committee Liaison: Chelsea Pinnix, MD, PhD
 Sarcoma Working Group Liaison: Jeremy Harris, MD
 Symptom Management & Survivorship
 Committee liaison: Erin Gillespie, MD, MPH
 Theranostics Subcommittee Chair: Jeffrey Wong, MD
 Theranostics Subcommittee Vice-Chair: Jeremie Calais, MD, PhD
 Theranostics Subcommittee Vice-Chair: Tanya Dorff, MD
 Data Coordinator: Larry Kaye

Time/Location

Thursday, May 1, 2025 3:00 p.m. - 5:00 p.m.
 Room: Seacliff CD (Bay Level)

3:32 - 3:47 pm	Phase II trial of response-adapted neoadjuvant therapy vs. total neoadjuvant therapy for locally advanced rectal cancer. - David Horowitz, MD
3:47 - 4:02 pm	CD8 T cell PET imaging before and after radiotherapy - Savita Dandapani, MD, PhD
4:02 - 4:17 pm	FES PET in breast cancer - Joanne Mortimer, MD
4:17 - 4:32 pm	Phase II randomized study of comparing total marrow and lymphoid irradiation (TMLI) with fractionated total body irradiation (FTBI) as conditioning for allogeneic peripheral blood stem cell hematopoietic cell transplantation (PBSC-HCT) in patients with acute lymphoblastic leukemia - Monzr Al Malki, MD and Jeffrey Wong, MD
4:32 - 4:47 pm	Addition of prostate directed external beam radiation to standard of care Lu-177 PSMA-617 therapy in patients with previously unirradiated PSMA avid prostatic disease - Ravi Patel, MD, PhD
4:47 - 4:52 pm	Follow up on: Phase III randomized study testing non-inferiority of short-course ultra-fractionated radiation (UHRT-5) versus standard fractionation (RT-25) for high-risk, resectable soft tissue sarcoma (S2505) - Jeremy Harris, MD
4:52 - 4:57 pm	Follow up on: Phase II study of Atezolizumab and Tocilizumab with radiotherapy in patients with newly diagnosed MGMT unmethylated GBM - Tony Wang, MD
4:57 - 5:00 pm	Closing Remarks - Chul S. Ha, MD

Agenda

3:00- 3:02 pm	Welcome - Chul S. Ha, MD
3:02 - 3:07 pm	Report from Executive Officer - Lisa Kachnic, MD
3:07 - 3:12pm	Update from IROC - Koren Smith, MS, MBA
3:12 - 3:17 pm	Update from NCI - Jacek Capala, Ph.D., DSc
3:17 - 3:32 pm	Early salvage vs. deferred image-guided salvage radiation therapy for recurrent prostate cancer post-prostatectomy in the PSMA-PET era - Martin Ma, MD, PhD

